Prevalence of Osteosarcopenic Obesity in Older Adults

May 16, 2020 updated by: Esma Nur KOLBAŞI, Istanbul Medeniyet University

Prevalence of Osteosarcopenic Obesity in Older Community-dwelling Adults in Turkey

Osteosarcopenic Obesity (OSO) is a syndrome characterized by the loss of bone and muscle in addition to increase in the fat tissue as a result of aging process. It is the latest point of impairment in the bone,muscle and adipose tissue in older adults. OSO, as the name suggests, is the combination of three syndrome frequently encountered in the elderly: osteopenia/osteoporosis, sarcopenia and obesity. The aims of study are to determine the prevalence of OSO syndrome in community-dwelling adults of Turkey and determine the possible factors regarding risk of falling in this population

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

460

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
      • Istanbul, Turkey, 34700
        • Goztepe Training and Research Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

65 years and older (Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

older adults at the age of 65 or over

Description

Inclusion Criteria:

  • Age of 65 or over
  • Being had been examined for all the primary outcome measures (i.e. the results of primary outcomes must be in the patient's file)

Exclusion Criteria:

  • Severe cognitive dysfunction
  • not being able to walk independently for 4 m

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
T score
Time Frame: 1 hour
T scores of spine and femur neck examined with Dual X-Ray Absorptiometry. A T score<-2,5 will be classified as osteoporosis while a T score between -1 and -2,5 will be counted as osteopenia
1 hour
Muscle Strength
Time Frame: 5 minutes
Measured by hand held dynamometer. The cut-off scores for man and woman are 27 kg and 16 kg, respectively
5 minutes
Muscle Mass
Time Frame: 2 minutes
Measured by bioimpedance analysis using Tanita TBF300. The cut-off scores for man and woman are 9,2 kg/m2 and 7,4 kg/m2, respectively
2 minutes
Muscle Performance
Time Frame: 3 minutes
Tested by 4 meter walk test. If the gait speed is lower than 0,8 m/s, the test is positive.
3 minutes
Obesity
Time Frame: 2 minutes
The fat percentage and the Body Mass Index measured by bioimpedance analysis using Tanita TBF300 is recorded. For BMI, 30 kg/m2 and over is classified as obesity whereas fat percentage of %35 and %28 (woman and man, respectively) and over was classified as obese.
2 minutes

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Comorbidity
Time Frame: 3 minutes
Using Charlson Comorbidity Index
3 minutes
History of falls
Time Frame: 1 minutes
A patient's self stated history of falls will be considered as having a history of fall or not.
1 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Istanbul Medeniyet University

Collaborators

Goztepe Training and Research Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 25, 2020

Primary Completion (Actual)

March 31, 2020

Study Completion (Actual)

April 1, 2020

Study Registration Dates

First Submitted

February 26, 2020

First Submitted That Met QC Criteria

February 26, 2020

First Posted (Actual)

February 28, 2020

Study Record Updates

Last Update Posted (Actual)

May 19, 2020

Last Update Submitted That Met QC Criteria

May 16, 2020

Last Verified

May 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IstanbulMU3

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Colombia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe